Survodutide

Survodutide is an investigational once-weekly injectable dual agonist of the glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor, developed for obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). It is also being studied for obesity with type 2 diabetes and cardiovascular outcomes.Survodutide Once Weekly for the Treatment of Adults with Obesity+2

The compound, also known as BI 456906, emerged from the idea that combining GLP-1 and glucagon receptor activation could produce greater weight loss and metabolic benefits than GLP-1 alone. Phase 2 and 3 studies have evaluated its effects on body weight, liver fat, and cardiometabolic risk factors.Survodutide Once Weekly for the Treatment of Adults with Obesity+2

In a large phase 3 trial of 725 adults with obesity but without diabetes, survodutide reduced body weight by 12.2% at 3.6 mg weekly and 13.0% at 6.0 mg weekly, compared with 5.4% on placebo, over 76 weeks. Most participants (72–73%) lost at least 5% of their starting weight.Survodutide Once Weekly for the Treatment of Adults with Obesity In another phase 3 trial of 216 adults with obesity and at-risk MASLD, 84.2% of those on 6.0 mg achieved at least a 30% reduction in liver fat at 48 weeks, compared with 24.3% on placebo, alongside a 12.2% weight loss.Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

These results place survodutide within a newer class of multi-target obesity therapies that aim to address not just weight but also liver health and cardiometabolic complications. However, the compound is not yet FDA-approved and remains in clinical development.Survodutide Once Weekly for the Treatment of Adults with Obesity+2

Survodutide works by activating two receptors that control appetite and metabolism: the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. GLP-1 is a hormone that reduces hunger and helps the body release insulin, while glucagon normally raises blood sugar but also boosts energy expenditure and fat breakdown in the liver. By targeting both receptors at once, survodutide aims to deliver stronger weight loss and liver fat reduction than GLP-1 drugs alone.Survodutide Once Weekly for the Treatment of Adults with Obesity+2

GLP-1 receptor activation slows stomach emptying, increases feelings of fullness after eating, and reduces calorie intake. Glucagon receptor activation adds an extra layer: it increases the body’s energy burn and directly speeds up the processing of liver fat. Together, these effects lead to sustained negative energy balance, meaning the body uses more stored fat for fuel.Survodutide Once Weekly for the Treatment of Adults with Obesity+2

In human trials, the dual action translated into substantial weight loss and liver fat improvement. People with obesity who took survodutide lost around 12–13% of their body weight over 76 weeks, compared with about 5% on placebo.Survodutide Once Weekly for the Treatment of Adults with Obesity In those with fatty liver disease, 84% had a clinically meaningful drop in liver fat after 48 weeks.Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial These outcomes support the idea that the glucagon component adds metabolic benefits beyond appetite suppression alone.

Importantly, these metabolic effects also ripple into other areas. The phase 3 programs are designed to measure changes in blood pressure, blood sugar, and kidney function, indicating that survodutide’s mechanism may improve overall cardiovascular and metabolic health in people with obesity-related complications.Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (<scp>SYNCHRONIZE™</scp>‐1 and ‐2)+2

The documented effects of survodutide come primarily from two large phase 3 randomized controlled trials.

Weight reduction in obesity In the SYNCHRONIZE-1 trial, 725 adults with obesity (average BMI 37.9) received survodutide or placebo once weekly for 76 weeks. Mean weight change at week 76 was -12.2% with 3.6 mg, -13.0% with 6.0 mg, and -5.4% with placebo. About 72% of people on either survodutide dose lost at least 5% of their body weight, compared to 46% on placebo.Survodutide Once Weekly for the Treatment of Adults with Obesity

Liver fat reduction in MASLD The SYNCHRONIZE-MASLD trial enrolled 216 adults with obesity and at-risk MASLD. After 48 weeks, 84.2% of the survodutide 6.0 mg group achieved at least a 30% reduction in liver fat (measured by MRI), versus 24.3% on placebo. Body weight fell by 12.2% with survodutide and 1.0% with placebo.Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

Additional metabolic benefits Beyond weight and liver fat, survodutide is expected to improve blood pressure, blood sugar, and other cardiometabolic risk factors, based on the endpoints included in the phase 3 program. Baseline data from these trials show that treated populations commonly had hypertension, prediabetes, or dyslipidemia, suggesting broad metabolic effects.Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (<scp>SYNCHRONIZE™</scp>‐1 and ‐2)+2

The weight loss effect is generally comparable across different populations, though the exact magnitude can vary depending on the analysis method (efficacy estimand vs. treatment-regimen estimand). The liver fat effect was particularly strong, making survodutide promising for people with fatty liver disease.Survodutide Once Weekly for the Treatment of Adults with Obesity+1

However, long-term data beyond 76 weeks are not yet available, and the effect on liver fibrosis or cardiovascular events remains under investigation in ongoing trials.Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial+1

Research protocols for survodutide follow a gradual dose escalation schedule, designed to minimize gastrointestinal side effects while increasing the dose to a target maintenance level. This approach mirrors the titration used in phase 3 trials.Survodutide Once Weekly for the Treatment of Adults with Obesity+1

Typical protocols in community practice start with a low dose, often 1.2 mg once weekly, and increase every 4 weeks as tolerated. Common step-ups are to 2.4 mg, then 3.6 mg, with an optional further step to 6.0 mg for those who tolerate it and need additional effect (community protocol; the specific starting dose and stepwise escalation are not detailed in the provided research).Survodutide Once Weekly for the Treatment of Adults with Obesity+1 The total treatment duration in studies ranged from 48 to 76 weeks, emphasizing continuous use rather than short cycles.

The best evidence supports a weekly subcutaneous injection, and no oral or intramuscular route has been studied in the provided research.Survodutide Once Weekly for the Treatment of Adults with Obesity+2 Community practice often recommends holding the dose or stepping back if side effects like nausea become bothersome, a strategy reflected in the trial design’s built-in dose flexibility.Survodutide Once Weekly for the Treatment of Adults with Obesity+1

After reaching the maintenance dose, treatment continues for months. The 76-week study provides the longest controlled data on sustained weight loss, and the 48-week MASLD study provides controlled liver fat data.Survodutide Once Weekly for the Treatment of Adults with Obesity+1 There is no evidence that abrupt discontinuation followed by re-starting (cycling) improves outcomes, and the trials were designed around continuous dosing.Survodutide Once Weekly for the Treatment of Adults with Obesity+1

For specific dose calculations and unit conversions, use the interactive reconstitution calculator in the next section. The tables there can help translate the milligram dose to syringe volumes for different vial configurations.

Survodutide is administered as a subcutaneous injection, and when prepared for research use, it is typically supplied as a lyophilized powder that requires reconstitution with a diluent. Bacteriostatic water is the standard choice for multi-dose vials, as it helps maintain sterility between uses. Sterile water is acceptable if the vial will be used quickly.[community protocol]

To reconstitute, inject the diluent slowly into the vial, directing the stream against the glass wall to avoid foaming, then swirl gently—never shake—to dissolve the powder. Once reconstituted, the solution should be clear and free of particles.[community protocol]

Storage before reconstitution: keep the lyophilized powder in the refrigerator (2–8°C) or freezer (-20°C for longer storage). After reconstitution with bacteriostatic water, the solution is typically used within 28–56 days when refrigerated; with sterile water, use within 7–14 days. Always return the vial to the refrigerator promptly after drawing the dose.[community protocol]

Because survodutide doses studied range from 1.2 mg to 6.0 mg, and research vials come in various sizes, the volume you inject depends on the concentration you prepare. Use the interactive reconstitution calculator below to determine the exact syringe volume for your desired dose. This removes the guesswork and helps ensure consistent dosing.

Survodutide’s effects on appetite, stomach emptying, and metabolism can interact with other medications. While no dedicated drug-drug interaction studies are reported in the available research, we can anticipate certain interactions based on its mechanism as a dual GLP-1/glucagon receptor agonist.Survodutide Once Weekly for the Treatment of Adults with Obesity+3

Key interactions to watch:

• Insulin and sulfonylureas: Because survodutide lowers blood glucose and reduces food intake, it can increase the risk of hypoglycemia if used with insulin or drugs that stimulate insulin release (like sulfonylureas). Careful glucose monitoring and possible dose reductions are advised.Baseline characteristics in the <scp>SYNCHRONIZE</scp> ™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/ <scp>GLP</scp> ‐1 receptor dual agonist, for obesity in people with type 2 diabetes+1
• Other GLP-1 drugs: Combining survodutide with semaglutide, liraglutide, tirzepatide, or similar agents is generally avoided in practice, as it adds GI side effects without clear added benefit.Survodutide Once Weekly for the Treatment of Adults with Obesity+2
• Oral medications: GLP-1 agonists slow stomach emptying, which could alter the absorption of some oral drugs, especially those that need quick absorption. This is less studied for survodutide specifically but is a known class effect.GLP-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Bridging Hepatic and Cardiovascular Outcomes
• Diuretics and blood pressure medications: Significant weight loss and reduced food/fluid intake can lower blood pressure. People on antihypertensives may need dose adjustments, and dehydration from GI side effects could compound diuretic effects.Survodutide Once Weekly for the Treatment of Adults with Obesity+2
• Alcohol: Alcohol can worsen nausea and dehydration, and in people with diabetes, it may increase hypoglycemia risk. Most users limit alcohol during dose escalation.Baseline characteristics in the <scp>SYNCHRONIZE</scp> ™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/ <scp>GLP</scp> ‐1 receptor dual agonist, for obesity in people with type 2 diabetes+1

For a full list and guidance on supplements, see the stacking section. The dominant risk factor for most interactions is the GI side effect profile—nausea, vomiting, or diarrhea—which can lead to dehydration and affect how other drugs are tolerated. During the first few weeks of dosage increases, it is especially important to monitor how you feel and review concurrent medications with a healthcare professional.

Survodutide is studied as a continuous, once-weekly treatment, not a short-term or intermittent therapy. The phase 3 obesity trials lasted 76 weeks, and the MASLD trial lasted 48 weeks, both with continuous dosing throughout.Survodutide Once Weekly for the Treatment of Adults with Obesity+2 There is no evidence from the research that scheduled periods off the drug (cycling) improve results or reduce side effects.

In practice, some people pause survodutide temporarily for two reasons:

• Tolerability: If nausea, vomiting, or other GI side effects become difficult to manage, a break of 1–4 weeks—followed by restarting at a lower dose—can help reset tolerance. This mirrors the built-in dose flexibility in clinical trials.Survodutide Once Weekly for the Treatment of Adults with Obesity+1
• Plateau: If weight loss stalls for many weeks despite adherence, some users take a short break to see if appetite suppression returns when restarting. However, this is not a formally studied strategy.

If you do pause, restarting at the previous high dose is not recommended. Instead, drop back one or two titration levels (e.g., from 6.0 mg to 3.6 mg or 2.4 mg) and escalate again slowly if needed.Survodutide Once Weekly for the Treatment of Adults with Obesity+2 The goal is to find the highest dose that is both effective and tolerable for long-term use.

Given that obesity is a chronic condition, the research supports sustained treatment rather than repeated on-off cycles. Stopping permanently will likely lead to weight regain, as seen with other obesity medications, though specific regain data for survodutide are not yet published.Survodutide Once Weekly for the Treatment of Adults with Obesity+1

Stacking survodutide with other compounds is common in research and community practice, but it is important to understand the potential synergies and risks.

Avoid stacking with other GLP-1 agonists. Survodutide already strongly activates GLP-1 receptors. Adding semaglutide, tirzepatide, liraglutide, or similar drugs is likely to increase nausea and GI side effects without additional benefit.Survodutide Once Weekly for the Treatment of Adults with Obesity+2

Combining with amylin analogs (e.g., cagrilintide) might enhance appetite suppression, but evidence is theoretical and the nausea risk could be high. Such combinations should only be tried with very slow titration and careful monitoring.[theoretical]

Anabolic or healing peptides (like BPC-157, TB-500, or growth hormone secretagogues) can be stacked with survodutide if nutrition is carefully managed. Survodutide’s strong appetite suppression may reduce protein and calorie intake, which could blunt the effectiveness of anabolic agents. Ensuring adequate protein and avoiding excessive caloric deficits are key.[community protocol]

Fat-loss stacks (caffeine, yohimbine, etc.) may worsen palpitations or nausea, especially during dose escalation. It is usually better to stabilize survodutide alone for several weeks before adding stimulants.[community protocol]

Supplements such as berberine, chromium, or fiber can add glucose-lowering or GI effects and should be introduced one at a time to identify tolerance.[theoretical]

A general rule in research is to change only one agent at a time and to wait 2–4 weeks before assessing effects. This makes it easier to attribute any side effects and avoids overwhelming the GI system.

As of the available research, survodutide is not approved for marketing by the FDA, EMA, or other major regulatory agencies. It is in the late stages of clinical development, with several phase 3 trials completed or ongoing for obesity, MASLD, and cardiovascular outcomes.Survodutide Once Weekly for the Treatment of Adults with Obesity+2

In the United States, this means it cannot be prescribed as a standard approved drug. Any availability outside of clinical trials would be through compounding or research channels, which are not FDA-assured for safety or efficacy.Survodutide Once Weekly for the Treatment of Adults with Obesity+1

Internationally, the situation is similar. There is no evidence of approval in the EU, UK, Australia, or Japan, though dedicated trials (such as SYNCHRONIZE-JP in Japan) indicate active development.Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (<scp>SYNCHRONIZE™</scp>‐1 and ‐2)+1

Anti-doping status: The provided research does not mention WADA or other sport organization listing for survodutide. As an investigational metabolic agent, it is not classified as a performance enhancer in the available sources, but athletes should always check the current WADA Prohibited List and with their sport’s governing body before use. The absence of a listed substance does not guarantee it is permitted.[practitioner consensus]

The most common side effects of survodutide in clinical research are gastrointestinal (GI) and are often dose-related. In the large obesity trial, GI symptoms were reported in 80.9% of those on 3.6 mg, 89.7% on 6.0 mg, and 47.9% on placebo. These were typically mild to moderate and included nausea, vomiting, diarrhea, constipation, reflux, and decreased appetite.Survodutide Once Weekly for the Treatment of Adults with Obesity In the MASLD trial, the pattern was similar, with GI issues most frequent during dose escalation.Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

These side effects tend to be most bothersome during the first few weeks of a dose increase. Many research protocols mitigate this by starting with a low dose and slowly escalating, as well as by encouraging small, low-fat meals and adequate hydration. If vomiting is severe or fluid intake cannot be maintained, a dose pause or reduction is recommended.Survodutide Once Weekly for the Treatment of Adults with Obesity+1

Less common but serious risks (based on class effects and theoretical concerns, as specific data are limited):

• Pancreatitis: Severe upper abdominal pain that radiates to the back should be evaluated immediately.
• Gallbladder issues: Rapid weight loss can increase gallstone formation risk; watch for right upper belly pain after meals.
• Hypoglycemia: Uncommon in people without diabetes, but risk increases if combined with insulin or sulfonylureas.Baseline characteristics in the <scp>SYNCHRONIZE</scp> ™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/ <scp>GLP</scp> ‐1 receptor dual agonist, for obesity in people with type 2 diabetes
• Dehydration and kidney stress: Severe GI losses can lead to acute kidney injury if fluid intake is not maintained.

Contraindications include prior serious allergic reaction, active severe GI intolerance, current pancreatitis, and pregnancy/breastfeeding (due to lack of data). Caution is needed in people with a history of pancreatitis, gastroparesis, advanced kidney disease, or eating disorders.Survodutide Once Weekly for the Treatment of Adults with Obesity+2

Monitoring during research protocols typically includes regular checks of weight, blood pressure, kidney function, liver enzymes, and blood sugar. The detailed monitoring section can guide testing schedules.Survodutide Once Weekly for the Treatment of Adults with Obesity+2